Recipharm is pleased to announce that Erdosteine will be tested in a clinical study as an add-on treatment for COVID-19 patients.
Erdosteine, which was discovered and developed in Italy by Recipharm’s facility in Paderno Dugnano, has been listed in the 2019 GOLD report.
Recipharm has signed an agreement with Daewoong, the leading Korean-based pharmaceutical company with a strong presence in respiratory therapeutics, for a 10-year extension of its existing contract for the manufacture and supply of Erdosteine API. The finished Erdosteine product is manufactured by Daewoong Pharmaceutical at its Korean facilities. Erdosteine is indicated for the treatment of acute and chronic respiratory diseases.
Market Place
Share
Share
